ALT (Altimmune, Inc.) Earnings per share growth in current year

Official company branding of Altimmune, Inc. (ALT)

Altimmune, Inc. (ALT) adheres to standard environmental regulations, minimizing its impact through production outsourcing. Business development relies on partnerships with laboratories for vaccine creation. The annual EPS growth rate captured this trend, and the parameter settled at 41.40. Looking ahead, Pemvidutide will provide significant pricing power due to its dual mechanism for muscle preservation during weight loss.

Earnings per share growth in current year: Altimmune Inc (ALT) for 07/04/2022 - 11/12/2026

Analytical breakdowns and data insights for company Altimmune, Inc. (ALT)

- market value and analyst target forecast:
Stock Price Altimmune Inc|ALT - Analyst Consensus Forecast
- business market valuation indicators:
Market Value Altimmune Pharma|ALT - Total Company Value
- book capitalization indicators:
Net Asset Value per Share Altimmune|ALT - Company Book Value|Market Value to Book Value Ratio altimmune.com|ALT - Company Total Assets
- debt and liquidity details:
Total Debt to Capital Coefficient Altimmune, Inc.|ALT - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient altimmune.com|ALT - Company Debts|Debt to Book Value Altimmune Pharma|ALT - Company Long-Term Debts|Company Short-Term Debts Altimmune|Quick Liquidity altimmune.com
- company profitability and valuation multiples indicators:
ALT - Net Income|Future Net Profit Altimmune, Inc.|ALT - P/E Multiple|Market Cap to Projected Earnings Altimmune Pharma|ALT - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Altimmune Pharma|ALT - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Altimmune|ALT - Net earnings per share for the last 12 months|Quarterly EPS earnings growth altimmune.com|ALT - Earnings per share growth in current year|Projected earnings per share growth rate for next year Altimmune, Inc.
Basic company analysis:ALT, Altimmune Inc
Mass-produced product of Altimmune

This indicator reflects the year-over-year dynamics of earnings per share, allowing for an assessment of value generation efficiency and business scaling rates. By analyzing the annual EPS growth rate in the context of Altimmune, Inc. (ALT) upgrading its peptide synthesis capacities, an investor can determine whether the technical readiness of the laboratories is translating into actual financial results, thereby avoiding the risks of asset overvaluation.

Direct competitors

Ascendis Pharma AS (ASND) - Earnings growth in current year|MDGL (Madrigal Pharma) - Earnings growth in current year|Earnings per share growth in current year CORT|Earnings per share growth in current year Rhythm Pharmaceuticals (RYTM)|AKRO - Earnings per share growth rate in current year|Earnings per share growth in current year Metsera MTSR|MoonLake Immunotherapeutics AG - Earnings per share growth in current year|Crinetics Pharma - Earnings growth in current year|Expected net earnings per share growth this year NewAmsterdam Pharma Corp NAMS|Soleno Therapeutics (SLNO) - Earnings per share growth in current year|FOLD - Expected net earnings per share growth this year|Earnings per share growth in current year 89bio|Net earnings per share growth this year Agios (AGIO)|Earnings growth in current year GPCR|Earnings growth in current year MiMedx Corp (MDXG)|Earnings per share growth in current year Rezolute, Inc. RZLT|lexpharma.com - Earnings per share growth in current year|MBX: Net earnings per share growth this year|Aardvark Therapeutics Inc. - Net earnings per one share growth for the current year|SGMT: Earnings growth in current year|BIOA - Expected net earnings per share growth this year|Earnings per share growth in current year Biomea Fusion, Inc.|Net earnings per share growth this year Quince (QNCX)|Earnings per share growth in current year Fractyl Health (GUTS)|Net earnings per share growth this year vtvtherapeutics.com VTVT|Agape ATP - Net earnings per share growth this year|Earnings growth in current year Pluristem Therapeutics PLUR|SYBX - Earnings per share growth in current year|LPCN (lipocine.com) - Earnings per share growth this year|MTNB: Earnings growth in current year|Earnings per share growth rate in current year sprucebiosciences.com (SPRB)|Net earnings per share growth this year GLTO|CTCX: Earnings per share increase in current year|Earnings growth in current year LUMO|Expected net earnings per share growth this year organovo.com|Earnings per share growth in current year Radius Recycling RDUS